On Thursday, Altera Corp. (NASDAQ:ALTR)’s shares climbed, as a semiconductor company, will offer a host of Ultra HD end-to-end solutions demonstrations at the 2015 National Association of Broadcasters convention (NAB) from April 13 to 16, in Las Vegas, at the Las Vegas Convention Center (Altera booth #SU10707). Featured for the first time will be the Altera multichannel, real-time H.265 hardware codec delivering a high quality full HD experience by implementing the Altera H.265 IP on a single chip with unprecedented quality and efficiency.
Altera will demonstrate how equipment makers can implement Ultra HD (UHD) products recently with 4K resolution, deeper color, and higher frame rates. Together with Oregano Systems, Altera is among the first vendors to offer a fully SMPTE-compliant sync solution, anticipating SMPTE’s imminent declaration of the publication of its time-labeling and clock synchronization standards, ST2059-1 and ST2059-2, critical to delivering IP-based video transport.
Altera Corporation, a semiconductor company, designs and sells programmable logic devices (PLDs), HardCopy application-specific integrated circuit (ASIC) devices, power system-on-chip devices (PowerSoCs), pre-defined design building blocks, and associated development tools.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s shares jumped during the last trading session on Thursday, as on April 2, in an interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis anticipates to hit the mark both for patients and investors.
The Life Sciences Report: Daniel, Sunesis Pharmaceuticals Inc. has been around for more than 15 years. How does the Sunesis of recently compare to its pioneering days?
Daniel Swisher: Sunesis was formed in 1998 with an initial focus on new discovery tools for small molecule drugs to address noteworthy unmet needs. Since then, we’ve become a late-stage development and pre-commercial company focused on oncology, thus leveraging our pioneering tyrosine kinase work. In addition, we attained worldwide rights for vosaroxin, our lead development product. What has remained constant is our strong focus on high-quality science and innovation.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
At the end of Thursday’s trade, Cimarex Energy Co. (NYSE:XEC)’s shares climbed, after an independent oil and gas exploration and production company declared that it plans to report first quarter 2015 financial results and provide an operational update after market close on Monday, May 4, 2015. The company will host its quarterly conference call at 11:00 AM EDT on Tuesday, May 5, 2015.
Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Texas, Oklahoma, and New Mexico. The company owns interests in 3,240 net productive oil and gas wells. As of December 31, 2014, it had a total proved oil and gas reserves of 3.1 trillion cubic feet equivalent (Tcfe) comprising of 1.7 trillion cubic feet of natural gas; and 0.7 Tcfe each of oil and natural gas liquids primarily located in the Permian Basin and Mid-Continent regions.
Integrated Device Technology, Inc. (NASDAQ:IDTI), ended its Thursday’s trading session in Green, after Integrated Device, declared that Robert A. Rango, a former Broadcom Corp. executive with extensive leadership skills in the global semiconductor market, has been designated to IDT’s Board of Directors, effective April 6, 2015.
Rango joined Broadcom in March 2002 and served in executive roles for over 12 years, most recently as executive vice president and general manager of Broadcom’s Mobile and Wireless Group, a role he had held since February 2011. During his time at Broadcom, Rango held several senior administration positions in the company’s Network Infrastructure Business Unit, Mobile and Wireless Group and Wireless Connectivity Group, counting as senior vice president and general manager, Wireless Connectivity Group and as executive vice president and general manager, Wireless Connectivity Group. From 1995 to 2002, Rango held several senior administration positions at Lucent Microelectronics and Agere Systems.
Rango also serves on the Board of Directors at KLA-Tencor. He has an MEEE from Cornell University and a BSEE from State University of New York at Stony Brook.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
